1. Home
  2. COHN vs CTXR Comparison

COHN vs CTXR Comparison

Compare COHN & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COHN
  • CTXR
  • Stock Information
  • Founded
  • COHN 1999
  • CTXR 2007
  • Country
  • COHN United States
  • CTXR United States
  • Employees
  • COHN N/A
  • CTXR N/A
  • Industry
  • COHN Investment Bankers/Brokers/Service
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • COHN Finance
  • CTXR Health Care
  • Exchange
  • COHN Nasdaq
  • CTXR Nasdaq
  • Market Cap
  • COHN 17.8M
  • CTXR 14.6M
  • IPO Year
  • COHN N/A
  • CTXR N/A
  • Fundamental
  • Price
  • COHN $6.97
  • CTXR $1.00
  • Analyst Decision
  • COHN
  • CTXR Strong Buy
  • Analyst Count
  • COHN 0
  • CTXR 2
  • Target Price
  • COHN N/A
  • CTXR $54.50
  • AVG Volume (30 Days)
  • COHN 9.6K
  • CTXR 638.0K
  • Earning Date
  • COHN 05-05-2025
  • CTXR 05-13-2025
  • Dividend Yield
  • COHN 14.14%
  • CTXR N/A
  • EPS Growth
  • COHN N/A
  • CTXR N/A
  • EPS
  • COHN N/A
  • CTXR N/A
  • Revenue
  • COHN $73,777,000.00
  • CTXR N/A
  • Revenue This Year
  • COHN N/A
  • CTXR N/A
  • Revenue Next Year
  • COHN N/A
  • CTXR N/A
  • P/E Ratio
  • COHN N/A
  • CTXR N/A
  • Revenue Growth
  • COHN N/A
  • CTXR N/A
  • 52 Week Low
  • COHN $6.10
  • CTXR $0.95
  • 52 Week High
  • COHN $12.82
  • CTXR $26.25
  • Technical
  • Relative Strength Index (RSI)
  • COHN 27.09
  • CTXR 27.13
  • Support Level
  • COHN $6.75
  • CTXR $0.95
  • Resistance Level
  • COHN $8.30
  • CTXR $2.28
  • Average True Range (ATR)
  • COHN 0.51
  • CTXR 0.21
  • MACD
  • COHN -0.12
  • CTXR -0.01
  • Stochastic Oscillator
  • COHN 8.89
  • CTXR 1.96

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: